Triple combination therapy for neovascular age-related macular degeneration was more cost-effective and dosed less frequently with supplemental zeaxanthin than without the supplement, according to a study. Age-related macular degeneration (AMD) affects an estimated 14 million people worldwide and is the leading cause of severe, irreversible vision loss in individuals over the age of 50 years. Ranibizumab is the current gold standard for the treatment of neovascular AMD. The drug binds and inhibits all isoforms of VEGF and thus improves visual acuity.
Despite impressive outcomes, treatment with ranibizumab requires sustained treatment regimens and frequent intravitreal injections. Another cost effective alternative to ranibizumab is treatment with bevacizumab. Bevacizumab has long been approved to treat different forms of cancer, but its application for AMD is debatable and not been…
